Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Application of Computational Techniques in Antibody Fc-Fused Molecule Design for Therapeutics.
Mol Biotechnol
April 2024
Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, Minden, Penang, Malaysia.
Since the advent of hybridoma technology in the year 1975, it took a decade to witness the first approved monoclonal antibody Orthoclone OKT39 (muromonab-CD3) in the year 1986. Since then, continuous strides have been made to engineer antibodies for specific desired effects. The engineering efforts were not confined to only the variable domains of the antibody but also included the fragment crystallizable (Fc) region that influences the immune response and serum half-life.
View Article and Find Full Text PDFMonoclonal Antibodies and Antibody-drug Conjugates as Emerging Therapeutics for Breast Cancer Treatment.
Curr Drug Deliv
May 2024
Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak, Haryana, 124001, India.
When breast cells divide and multiply out of control, it is called breast cancer. Symptoms include lump formation in the breast, a change in the texture or color of the breast, or a discharge from the nipple. Local or systemic therapy is frequently used to treat breast cancer.
View Article and Find Full Text PDFGenetic code expansion in E. coli enables production of a functional 'ready-to-click' T cell receptor-specific scFv.
N Biotechnol
September 2023
acib - Austrian Centre of Industrial Biotechnology, Petersgasse 14, 8010 Graz, Austria; Institute of Molecular Biotechnology, Graz University of Technology, Petersgasse 14, 8010 Graz, Austria; Institute of Bioprocess Science and Engineering, Department of Biotechnology, University of Natural Resources and Life Sciences, Muthgasse 18, 1190 Vienna, Austria. Electronic address:
Article Synopsis
- Antibody-based cancer therapies, particularly bispecific antibody-drug conjugates, are advancing quickly in the pharmaceutical industry, enhancing immunotherapy's effectiveness.
- Miniaturized antibody fragments like diabodies, nanobodies, and scFvs show great potential for targeting and penetrating tumor tissues in cancer treatments.
- This study developed a versatile scFv OKT3 antibody using E. coli, incorporating a unique amino acid for efficient 'click chemistry' conjugation, intending for applications in controlled anti-T cell therapies and cancer imaging.
Development of the first reference antibody panel for qualification and validation of cytokine release assay platforms - Report of an international collaborative study.
Cytokine X
December 2020
Novartis Institutes for BioMedical Research, Klybeckstrasse 141, Basel CH-4002, Switzerland.
Immunomodulatory therapeutics such as monoclonal antibodies (mAb) carry an inherent risk of undesired immune reactions. One such risk is cytokine release syndrome (CRS), a rapid systemic inflammatory response characterized by the secretion of pro-inflammatory cytokines from immune cells. It is crucial for patient safety to correctly identify potential risk of CRS prior to first-in-human dose administration.
View Article and Find Full Text PDFRevisiting the phenotypic and genetic profiling of anergic T cells mediating long-term transplant tolerance.
Curr Opin Organ Transplant
February 2018
Université Paris Descartes, Sorbonne Paris Cité.
Purpose Of Review: Herein our focus will be to revisit peripheral tolerance mechanisms and in particular 'active' or 'dominant' tolerance as originally defined and mediated by regulatory CD4FoxP3 T lymphocytes (Treg) and also T-cell anergy that appears as a major mainstay to support long-term allograft survival.
Recent Findings: It is at the same time interesting and rewarding that the tool that recently guided our efforts along this path is the in-vivo use of CD3 antibody, the first monoclonal introduced in the clinic (Orthoclone OKT3) about 35 years ago to treat and prevent rejection of renal allografts. Beyond their immunosuppressive activity, whenever administered judiciously, CD3 antibodies promote robust allograft tolerance through selective purging of alloreactive effectors, resetting Treg-mediated active tolerance and promoting a unique subset of anergic CD8 T cells.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!